Navigation Links
Eaton Scientific Systems, Ltd. completes its Study Protocol for its Planned Clinical Trial of its Patent Pending Non-Hormonal Treatment of Hot Flashes.
Date:9/6/2012

BEVERLY HILLS, Calif., Sept. 6, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce that it has completed the Protocol for the Clinical Trial for Tropine 3, its novel indication of homatropine, in oral suspension to be prescribed to women afflicted with hot flashes during pre-menopause, peri-menopause, and post-menopause. 

Eaton CEO, Michael Borkowski, announced today that Eaton has a complete Protocol that is the guideline for Eaton's Clinical Trial. "This is a very important step in the process of seeking FDA Approval for Tropine 3 and illustrates our progress towards the Clinical Trial."

The Protocol and proposed Clinical Trial will be a Phase I/II, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Open Label Study to Test the Efficacy and Safety of Homatropine Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving HRT.

Homatropine methylbromide has been used as a drug in humans for over 50 years.  Currently, it is used to discourage overdose in the popular narcotic cough syrup Hycodan.

Due to the long established use of homatropine methylbromide, the usual bench toxicity and animal studies will not be performed for this IND application.  Instead, a combined phase I/II design will be used.  This design incorporates both dose-finding rules and early stopping rules in terms of response and toxicity, thus combining elements of more typical Phase I and Phase II designs.

About Pristine Solutions, Inc.
Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, peri-menopausal, and post-menopausal women.   

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Eaton Scientific Systems, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
2. Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Womens Health and Drug Sector
3. Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in Menopausal Women
4. Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
5. Eaton Scientific Discusses Positive Anecdotal Feedback from Pharmacist Compounding Homatropine for Doctors Treating Patients Experiencing Hot Flash Symptoms in the Beverley Hills and Los Angeles Area.
6. Eaton Scientific Enters Agreement with RoxSan Pharmacy to Provide Tropine 3 for its upcoming Clinical Trial Participants
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
9. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
10. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
11. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Neurim Pharmaceuticals ("Neurim") and Exeltis ... marketing rights for Neurim,s new Rx PedPRM in Spain ... Neurim,s ... disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. ... children. The collaboration with Exeltis will help increase the ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits ... published by New Frontier Data, the legal cannabis market is projected ... legalization in the United States , as well ... a major factor that drives growth in this sector. Medical cannabis ...
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ... of Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee ... Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the official ... Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony on ... of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than 1,400 ...
(Date:3/28/2017)... ... 28, 2017 , ... Tuesday, March 28, 2017, is the annual American Diabetes ... Risk Test to find out if they are at risk for developing Type 2 ... the evening sky by programming the LAX pylons the color red. Downtown’s U.S. Bank ...
(Date:3/28/2017)... Georgia (PRWEB) , ... March 28, 2017 , ... ... to its award-winning team. Ruel Williamson brings his extensive knowledge of appraisals, property ... a leader in the real estate valuation industry for more than 40 years. ...
(Date:3/28/2017)... ... , ... The Thyroid Secret is a specialized 9-part documentary ... was recently launched on March 1, and Dr. Wentz discussed varied benefits and ... Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. After being ...
Breaking Medicine News(10 mins):